DR10627

**DR10627** is an investigational long-acting incretin peptide agonist being developed for metabolic disease, initially including **obesity** and **type 2 diabetes mellitus**. Published preclinical data describe it as a **dual agonist of the glucagon-like peptide 1 receptor and gastric inhibitory polypeptide receptor**, while company pipeline materials and commercial pipeline databases also describe it as a **triple agonist targeting glucagon-like peptide 1 receptor, gastric inhibitory polypeptide receptor, and glucagon receptor**, suggesting the program description may have evolved over time or differs across sources. The molecule is reported to be a **chemically synthesized 39-amino-acid peptide** based on the GLP-1 sequence with mutations conferring GIP activity and **long-chain fatty-acid conjugation** to extend half-life. It has shown glucose-lowering and weight-loss activity in preclinical models, and external pipeline sources indicate the program has reached **Phase 1** development in China under Doer Biologics and affiliated organizations.